. Changes in the circulating tumor DNA concentration post-NAC compared with measured pre-NAC in (A) NAC-sensitive and (B) resistant patient groups. The statistical analyses were performed using the Mann-Whitney U test. P<0.05 was considered to indicate a statistically significant difference. NAC, neoadjuvant chemotherapy.
. Genotype and VAF of TP53 mutation in NAC-sensitive and resistant patient groups. Nine sites of TP53 mutation were detected. In NAC-sensitive cases, VAF in post-NAC was decreased as compared to pre-NAC. In NAC-resistant cases, VAF in post-NAC was increased compared as to pre-NAC. VAF, variant allele frequency; NAC, neoadjuvant chemotherapy.
